Bispecific antibodies and B-cell lymphoma: A new immunotherapy routinely available for patient management (notice n° 174728)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01328cam a2200169 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040003.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gilardoni, Aliénor |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Bispecific antibodies and B-cell lymphoma: A new immunotherapy routinely available for patient management |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 63 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | New therapies involving T lymphocytes are playing an increasingly important role in the management of refractory B-cell non-Hodgkin lymphoma (B-NHL), with chimeric antigen receptor T cells (CAR-T cells) available to patients as early as for second-line treatment in some cases. However, these treatments are associated with significant organizational challenges, as well as failure rates in more than half of cases. Bispecific antibodies therefore complement the therapeutic armory for B-NHL. Encouraging response rates are gradually extending their indications to the various types of B-NHL, offering a new option with the advantage of immediate availability. In this article, we summarize the current indications and recent advances of bispecific antibodies in B-NHL. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sarkozy, Clémentine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 30 | 1 | 2024-06-01 | p. 46-60 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hematologie-2024-1-page-46?lang=en">https://shs.cairn.info/journal-hematologie-2024-1-page-46?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux